Fiasp

Active Ingredient(s): Insulin Aspart
FDA Approved: * September 29, 2017
Pharm Company: * NOVO NORDISK INC
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Fiasp Overview

Insulin aspart is a fast-acting insulin analog marketed by Novo Nordisk as NovoLog/NovoRapid. It is a manufactured form of human insulin; where a single amino acid has been exchanged. This change helps the fast-acting insulin analog be absorbed quickly into the bloodstream. As a result, it starts working in minutes, which allows one to take insulin and eat right away. Fast-acting insulin analogs are considered to act similarly to the way insulin is released in people without diabetes mellitus...

Read more Fiasp Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Insulin_aspart

Recent Fiasp Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Fiasp: (2 results)

Sorted by National Drug Code

• 0169-3201 Fiasp 100 [Iu]/Ml Subcutaneous Injection, Solution by Novo Nordisk
• 0169-3204 Fiasp 100 [Iu]/Ml Subcutaneous Injection, Solution by Novo Nordisk

Other drugs which contain Insulin Aspart or a similar ingredient: (6 results)